Advertisement
AZR vs SYRE
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is AZR is a Buy and SYRE is a Hold.
AZR's MACD Histogram crosses above signal line
The Moving Average Convergence Divergence (MACD) for AZR turned positive on October 20, 2026. Looking at past instances where AZR's MACD turned positive, the stock continued to rise in 40 of 44 cases over the following month. The odds of a continued upward trend are 90%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where AZR's RSI Indicator exited the oversold zone, 28 of 32 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 88%.
The Momentum Indicator moved above the 0 level on October 21, 2026. You may want to consider a long position or call options on AZR as a result. In 86 of 101 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 85%.
Following a +37.23% 3-day Advance, the price is estimated to grow further. Considering data from situations where AZR advanced for three days, in 157 of 207 cases, the price rose further within the following month. The odds of a continued upward trend are 76%.
Bearish Trend Analysis
The Stochastic Oscillator has been in the overbought zone for 1 day. Expect a price pull-back in the near future.
AZR moved below its 50-day moving average on October 30, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for AZR crossed bearishly below the 50-day moving average on September 28, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 11 of 12 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 90%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where AZR declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
AZR broke above its upper Bollinger Band on October 28, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for AZR entered a downward trend on October 26, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Price Growth Rating for this company is 34 (best 1 - 100 worst), indicating steady price growth. AZR’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 35 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (-0.386) is normal, around the industry mean (3.162). P/E Ratio (-0.285) is within average values for comparable stocks, (-1.064). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (131.622) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (439.647).
The Tickeron PE Growth Rating for this company is 96 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. AZR’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
SYRE's Stochastic Oscillator remains in overbought zone for 7 days
The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
Technical Analysis (Indicators)
Bearish Trend Analysis
The 10-day RSI Indicator for SYRE moved out of overbought territory on October 29, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 27 similar instances where the indicator moved out of overbought territory. In 24 of the 27 cases, the stock moved lower in the following days. This puts the odds of a move lower at 89%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where SYRE declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 87%.
The Aroon Indicator for SYRE entered a downward trend on October 01, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 20, 2026. You may want to consider a long position or call options on SYRE as a result. In 70 of 78 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 90%.
The Moving Average Convergence Divergence (MACD) for SYRE just turned positive on October 20, 2026. Looking at past instances where SYRE's MACD turned positive, the stock continued to rise in 35 of 42 cases over the following month. The odds of a continued upward trend are 83%.
SYRE moved above its 50-day moving average on October 26, 2026 date and that indicates a change from a downward trend to an upward trend.
The 10-day moving average for SYRE crossed bullishly above the 50-day moving average on October 29, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 9 of 14 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 64%.
Following a +7.36% 3-day Advance, the price is estimated to grow further. Considering data from situations where SYRE advanced for three days, in 259 of 298 cases, the price rose further within the following month. The odds of a continued upward trend are 87%.
SYRE may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 5 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (8.918) is normal, around the industry mean (3.162). P/E Ratio (-50.308) is within average values for comparable stocks, (-1.064). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (131.622) among similar stocks. P/S Ratio (526.316) is also within normal values, averaging (439.647).
The Tickeron Price Growth Rating for this company is 35 (best 1 - 100 worst), indicating steady price growth. SYRE’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 44 (best 1 - 100 worst), pointing to consistent earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 96 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. SYRE’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
AZR | SYRE | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 11 | 50 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 35 Fair valued | 5 Undervalued | |
PROFIT vs RISK RATING 1..100 | 100 | 100 | |
SMR RATING 1..100 | 100 | 96 | |
PRICE GROWTH RATING 1..100 | 34 | 35 | |
P/E GROWTH RATING 1..100 | 96 | 44 | |
SEASONALITY SCORE 1..100 | 50 | n/a |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
SYRE's Valuation (5) in the Pharmaceuticals Major industry is in the same range as AZR (35). This means that SYRE’s stock grew similarly to AZR’s over the last 12 months.
SYRE's Profit vs Risk Rating (100) in the Pharmaceuticals Major industry is in the same range as AZR (100). This means that SYRE’s stock grew similarly to AZR’s over the last 12 months.
SYRE's SMR Rating (96) in the Pharmaceuticals Major industry is in the same range as AZR (100). This means that SYRE’s stock grew similarly to AZR’s over the last 12 months.
AZR's Price Growth Rating (34) in the Pharmaceuticals Major industry is in the same range as SYRE (35). This means that AZR’s stock grew similarly to SYRE’s over the last 12 months.
SYRE's P/E Growth Rating (44) in the Pharmaceuticals Major industry is somewhat better than the same rating for AZR (96). This means that SYRE’s stock grew somewhat faster than AZR’s over the last 12 months.
| AZR | SYRE | |
|---|---|---|
| RSI ODDS (%) | 4 days ago 88% | 4 days ago 89% |
| Stochastic ODDS (%) | 4 days ago 90% | 4 days ago 90% |
| Momentum ODDS (%) | 4 days ago 85% | 4 days ago 90% |
| MACD ODDS (%) | 4 days ago 90% | 4 days ago 83% |
| TrendWeek ODDS (%) | 4 days ago 90% | 4 days ago 87% |
| TrendMonth ODDS (%) | 4 days ago 90% | 4 days ago 88% |
| Advances ODDS (%) | 6 days ago 76% | 6 days ago 87% |
| Declines ODDS (%) | 4 days ago 90% | 4 days ago 87% |
| BollingerBands ODDS (%) | 4 days ago 90% | 4 days ago 86% |
| Aroon ODDS (%) | 4 days ago 90% | 4 days ago 89% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
AZR’s FA Score shows that 0 FA rating(s) are green while SYRE’s FA Score has 1 green FA rating(s).
- AZR’s FA Score: 0 green, 5 red.
- SYRE’s FA Score: 1 green, 4 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
AZR’s TA Score shows that 4 TA indicator(s) are bullish while SYRE’s TA Score has 6 bullish TA indicator(s).
- AZR’s TA Score: 4 bullish, 6 bearish.
- SYRE’s TA Score: 6 bullish, 4 bearish.
Price Growth
AZR (@Biotechnology) experienced а -2.81% price change this week, while SYRE (@Biotechnology) price change was +6.90% for the same time period.
The average weekly price growth across all stocks in the @Biotechnology industry was +0.20%. For the same industry, the average monthly price growth was -14.01%, and the average quarterly price growth was -15.33%.
Reported Earning Dates
AZR is expected to report earnings on Nov 12, 2026.
SYRE is expected to report earnings on Nov 03, 2026.
Industries' Descriptions
@Biotechnology (+0.20% weekly)Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
Advertisement
AZR and
Correlation & Price change
A.I.dvisor indicates that over the last year, AZR has been loosely correlated with SYRE. These tickers have moved in lockstep 39% of the time. This A.I.-generated data suggests there is some statistical probability that if AZR jumps, then SYRE could also see price increases.
| Ticker / NAME | Correlation To AZR | 1D Price Change % | ||
|---|---|---|---|---|
| AZR | 100% | -20.79% | ||
| SYRE - AZR | 39% Loosely correlated | -2.43% | ||
| VANI - AZR | 37% Loosely correlated | -4.39% | ||
| VTVT - AZR | 29% Poorly correlated | -4.59% | ||
| GMAB - AZR | 28% Poorly correlated | +1.01% | ||
| GDTC - AZR | 27% Poorly correlated | -0.66% | ||
More | ||||
| 1 Day | |||
|---|---|---|---|
| ETFs / NAME | Price $ | Chg $ | Chg % |
| PRIV | 24.40 | 0.08 | +0.33% |
| SPDR SSGA Apollo IG Public & Private Credit ETF | |||
| MINT | 100.74 | 0.07 | +0.07% |
| PIMCO Enhanced Short Maturity Active Exchange-Traded Fund (MINT) | |||
| TOCT | 27.42 | N/A | N/A |
| Innovator 2 Yr to October 2027 (TOCT) | |||
| IFV | 23.75 | -0.24 | -1.01% |
| First Trust Dorsey Wright International Focus 5 ETF (IFV) | |||
| FFEM | 37.69 | -1.13 | -2.92% |
| Fidelity Fundamental Emerging Markets ETF | |||